Abstract Epidermal Growth Factor Receptor (EGFR) enacts major roles in the maintenance
of epithelial tissues. However, when EGFR signaling is altered, it becomes the grand …

Epidermal growth factor receptor (EGFR) mutations are the second most common oncogenic
driver event in non-small cell lung cancer (NSCLC). Classical activating mutations (exon 19 …

The first-line treatment of choice for patients with epidermal growth factor receptor (EGFR)
mutation-positive non-small cell lung cancer (NSCLC) is an EGFR tyrosine kinase inhibitor …

In the past two decades, several molecular targeted inhibitors have been developed and
evaluated clinically to improve the survival of patients with cancer. Molecular targeted …

Uncommon Epidermal Growth Factor Receptor (EGFR) mutations represent a distinct and
highly heterogeneous subgroup of Non-Small Cell Lung Cancers (NSCLCs), that accounts …

Purpose We tried to evaluate whether there are any specific features in treatment outcomes
of firstline afatinib in patients with epidermal growth factor receptor (EGFR)-mutant non-small …

Abstract Objective Approximately 10%–15% patients with epidermal growth factor receptor
(EGFR) mutations harbor non-classical mutations. However, the effects of EGFR-tyrosine …

Simple Summary The advent of epidermal growth factor receptor (EGFR) tyrosine kinase
inhibitors (EGFR-TKIs) has led to a dramatic improvement in the prognosis of patients …

Introduction Non-small cell lung cancer (NSCLC) harbouring EGFR exon 19 deletions or
L858R mutation usually respond to epidermal growth factor receptor–tyrosine kinase …

Objectives Advanced non-small cell lung cancer (NSCLC) patients harboring non-resistant
uncommon epidermal growth factor receptor (EGFR) mutations have stepped into the era of …